Ransomware victim disclosure
← All victimsGlenmark Pharmaceuticals
listed as glenmarkpharma.com · Claimed by INC Ransom · listed 2 months ago
Status timeline
- Listed
Mar 25, 2026
- Data leaked
At a glance
- Group
- INC Ransom
- Status
- Data leaked
- Country
- India
- Sector
- Healthcare
- Listed on leak site
- Mar 25, 2026
- Records
- 032. Email
About the victim
AI dossier — public-source company profileGlenmark Pharmaceuticals is a global pharmaceutical company founded in 1977 and headquartered in Mumbai, India. The company develops, manufactures, and markets pharmaceutical products across more than 80 countries, with operations spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. It employs over 16,000 people globally, operates 11 manufacturing facilities and 6 R&D centres, and focuses on both innovative therapies and generic medicines.
- Industry
- Pharmaceutical Manufacturing & R&D
- Address
- Glenmark Pharmaceuticals Ltd., Corporate Headquarters, Mumbai, India
- Employees
- 16000+
- Founded
- 1977
Attack summary
Severity: critical — Data has been published (not merely claimed) by the group against a publicly listed multinational pharmaceutical company with 16,000+ employees operating in 80+ countries. The exposure includes named senior executives and compliance/investor contacts, and the pharmaceutical sector context means broader regulated data (clinical, financial, IP) is highly likely part of the full exfiltration. The scale of the organisation and the published nature of the disclosure elevate this to critical.INC Ransom claims to have exfiltrated data from Glenmark Pharmaceuticals, with the disclosure status marked as data_published, indicating stolen data has been released. The leaked post exposes named senior executives (including C-suite and VP-level personnel), investor contact details, compliance officer information, and business development contacts.
Data the group says was taken
AI dossier — extracted from the leak post- Senior executive personally identifiable information (names, titles)
- Corporate officer contact details
- Investor relations contact information
- Compliance officer email and phone numbers
- Business development contact information
- Registrar and share transfer agent details
What the group claims
Glenmark Pharmaceuticals, founded in 1977 and headquartered in Mumbai, India, is a global pharmaceutical company that develops, manufactures, and markets pharmaceutical products. The company operates in over 25 countries across North America, South America, Europe, Asia, Africa, and the Middle East, with a strong focus on research and development of innovative medications. Glenmark specializes in various therapeutic areas and maintains a diverse portfolio of pharmaceutical products serving both business and consumer markets worldwide. Rajeev Sharma Senior Vice President and Chief Financial Officer - North America Laura Lester Senior Vice President & General Counsel - North America Jim Brown Senior Vice President Firas B Abulaban Senior Vice President and Corporate Quality Head of North America Bradley Nowels Vice President Institutional Sales – North America Vishal Arora Vice President of Business Development and Licensing Michael Pope Executive Director and Site Head – Monroe, NC Adam Subervi Chief Compliance Officer Fabio Moreno Executive Director and Head of the OTC Business Kathleen (Kathy) McKenna Senior Director – Human Resources INVESTORS Company Secretary & Compliance Officer [email protected] Tel No.: +91 22 4018 9999 Fax No.: +91 22 4018 9986 REGISTRAR AND SHARE TRANSFER AGENTS KFIN Technologies Limited Selenium Building, Tower-B, Plot No 31 & 32,Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana, India – 500 032. Email ID: [email protected] Toll Free/ Phone Number : 1800 309 4001 WhatsApp Number : (91) 910 009 4099 KFINTECH Corporate Website: www.kfintech.com RTA Website: https://ris.kfintech.com Investor Support Centre (DIY Link) https://ris.kfintech.com/clientservices/isc BUSINESS DEVELOPMENT For queries related to collaboration and partnership, please email to : [email protected] INVESTORS Company Secretary & Compliance Officer
Sources
- Victim siteglenmarkpharma.com
Source
Indexed 2 months agoThis page surfaces a public ransomware disclosure indexed by Darkfield. Original posts come from the operator's own leak site; we cross-check against ransomware.live, RansomLook and RansomWatch where applicable. Share this URL freely.